Blue Water Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Greenwich, Connecticut.
IPO Year: 2020
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
GREENWICH, Conn., June 11, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company") (NASDAQ:BLUWU), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chairman and Chief Executive Officer Joseph Hernandez, today announced the closing of its upsized initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option, at an offering price of $10.00 per unit, resulting in gross proceeds of $253,000,000. The Company'
GREENWICH, Conn., June 10, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chairman and Chief Executive Officer Joseph Hernandez, today announced the upsized pricing of its initial public offering of 22,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. The units are expected to trade on The Nasdaq Global Market ("Nasdaq")under the ticker symbo
GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ:BLUW), a special purpose acquisition company ("Blue Water"), today announced that its stockholders have voted to approve the proposed business combination (the "Business Combination") with Clarus Therapeutics, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women ("Clarus") at its special meeting of stockholders (the "Special Meeting") held today, August 27, 2021. Holders of approximately 73.95% of Blue Water's issued and outstanding shares cast votes at the Special Meeting. Approximately 69.57% o
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ: BLUW) ("Blue Water" or the "Company"), a special purpose acquisition company (SPAC) that previously announced a planned business combination with Clarus Therapeutics, Inc. ("Clarus"), announced today that the special meeting of its stockholders (the "Special Meeting") originally scheduled for Thursday, August 12, 2021, is being postponed to Friday, August 27, 2021. As a result of this change, the Special Meeting will now be held at 10:00 a.m., Eastern Time, on August 27, 2021, exclusively via a live audio webcast at https://www.cstproxy.com/bluewateracquisition/2021. Also as a result of this c
New York, NY, April 22, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ:BLUWU) (the "Company") announced today that it received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule") because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2020 (the "Form 10-K") with the Securities and Exchange Commission ("SEC"). The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. As previously disclosed in the Current Report on Fo
EFFECT - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
424B3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
S-1 - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
25-NSE - Blue Water Acquisition Corp. (0001817944) (Subject)
8-K - Blue Water Acquisition Corp. (0001817944) (Filer)
8-K - Blue Water Acquisition Corp. (0001817944) (Filer)
425 - Blue Water Acquisition Corp. (0001817944) (Subject)
4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
4/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
SC 13G - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
SC 13D - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
SC 13G - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
SC 13G/A - Blue Water Acquisition Corp. (0001817944) (Subject)
SC 13G - Blue Water Acquisition Corp. (0001817944) (Subject)
SC 13G - Blue Water Acquisition Corp. (0001817944) (Subject)